Names and pronunciation
(ehz-eh-tim′bee) Ezetrol , Zetia
Source page 541
Loading InternPractice…
Individual generic drug information
Extracted information for ezetimibe only.
(ehz-eh-tim′bee) Ezetrol , Zetia
Source page 541
Func. class.: Antilipemic; cholesterol absorption inhibitor
Source page 541
ACTION: Inhibits absorption of cho- lesterol by the small intestine, causes reduced hepatic cholesterol stores
Source page 541
USES: Hypercholesterolemia, homo- zygous familial hypercholesterolemia (HoFH), homozygous sitosterolemia
Source page 541
Extracted information for ezetimibe only.
CONTRAINDICATIONS: Hyper- sensitivity, severe hepatic disease Precautions: Pregnancy, breastfeeding, children, hepatic disease
Source page 541
SIDE EFFECTS CNS: Fatigue, dizziness, headache GI: Diarrhea, abdominal pain MISC: Chest pain MS: Myalgias, arthralgias, back pain, myopathy, rhabdomyolysis RESP: Pharyngitis, sinusitis, cough, URI EENT: Sinusitis, nasopharyngitis SYST: Angioedema
Source page 541
INTERACTIONS Increase: action of ezetimibe—fibric acid derivatives, cycloSPORINE E Decrease: action of ezetimibe—antac- ids, bile acid sequestrants Drug/Lab Test Increase: LFTs
Source page 541
Extracted information for ezetimibe only.
DOSAGE AND ROUTES • Adult/adolescent/child >10 yr: PO 10 mg/day
Source page 541
Available forms: Tablets 10 mg
Source page 541
Administer: Without regard to meals • Separate by ≥2 hr prior to or ≥4 hr after bile acid sequestrant, may use with HMG-CoA reductase inhibitors
Source page 541
Extracted information for ezetimibe only.
Assess: • Hypercholestrolemia: diet history: fat content, lipid levels (triglycerides, LDL, HDL, cholesterol); LFTs at baseline, peri- odically during treatment • Myopathy/rhabdomyolysis: increased CPK, myalgia, muscle cramps, musculo- skeletal pain, lethargy, fatigue, fever; more common when combined with statins • Pregnancy/breastfeeding: do not use in pregnancy, breastfeeding
Source page 541
Evaluate: • Therapeutic response: decreased cho- lesterol, LDL; increased HDL
Source page 541
CLINICAL CONSIDERATIONS
Source page 541
Patient and caregiver information: • That compliance is needed • That risk factors should be decreased: high-fat diet, smoking, alcohol consump- tion, absence of exercise • To notify prescriber if pregnancy sus- pected, planned, or if breastfeeding • To notify prescriber if unexplained weakness, muscle pain present • To notify prescriber of dietary/herbal supplements
Source page 541
Extracted information for ezetimibe only.
PHARMACOKINETICS Absorption variable, metabolized in small intestine, liver; excreted in feces 78%, urine 11%; peak 4-12 hr; half- life 22 hr
Source page 541
Filter the extracted dose blocks for this individual drug.
• Adult/adolescent/child >10 yr: PO 10 mg/day
Candidate age grouping · source page 541